Abstract：
:We investigated whether or not mutations at codon 215 in the HIV reverse-transcriptase-encoding gene predicted a lower efficacy of didanosine therapy, as defined by survival of patients and change in CD4 cell counts in 121 HIV-infected, zidovudine-experienced patients. A trend for shorter survival, although not reaching significance, was observed for patients with HIV strains with the reverse transcriptase codon 215 mutation (P = 0.07), but this trend disappeared after adjustment for initial CD4 cell counts. During the first 3 months on didanosine therapy, the increase in CD4 cell counts was greater in patients who were wild type at codon 215 than in those with the mutation at codon 215 (P = 0.03). These data suggest that there was a better initial CD4 response to didanosine therapy in patients with HIV without the mutation at codon 215, but that this response did not translate into increased survival.
journal_name
Antivir Therjournal_title
Antiviral therapyauthors
Yerly S,Denereaz N,Mermillod B,Hirschel B,Perrin Lsubject
Has Abstractpub_date
1996-08-01 00:00:00pages
167-71issue
3eissn
1359-6535issn
2040-2058journal_volume
1pub_type
杂志文章abstract：BACKGROUND:Drug-resistant HBV mutants frequently arise during nucleoside/nucleotide analogue (NA) therapy, while the resistance mutations on polymerase also have consequent changes in the S protein. The enrichment of immune-escape mutations was negatively correlated with hepatitis B surface antigen (HBsAg) clearance un...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3156
更新日期：2017-01-01 00:00:00
abstract：OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章,随机对照试验
doi：
更新日期：2003-10-01 00:00:00
abstract：:Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1302
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Mutations in the genome of HIV conferring drug resistance are a major reason for the failure of antiretroviral therapy, but they often compromise viral fitness. Protease (PR) cleavage site (CS) mutations could compensate for impaired replication capacity of drug-resistant viruses. PATIENTS AND METHODS:We an...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：:Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B is difficult to treat and there is little long-term data for lamivudine treatment of severe acute exacerbation. We report a prospective, consecutive cohort of severe acute exacerbation of HBeAg-negative chronic hepatitis B patients treated by lamivudine betwee...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Although thiazolidinediones have been shown to increase subcutaneous fat in congenital lipodystrophy, rosiglitazone did not show convincing results in HIV lipoatrophy. We assess a potential specific effect of pioglitazone in this setting. METHODS:One-hundred and thirty HIV-1-infected adults with self-report...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究,随机对照试验
doi：
更新日期：2008-01-01 00:00:00
abstract：:Combinations of two nucleoside analogue reverse transcriptase inhibitors plus a third agent represent the current standard for antiretroviral therapy. Stavudine is a nucleoside analogue that demonstrates in vitro activity against human immunodeficiency virus type 1 (HIV-1) and HIV-2 within an acceptable therapeutic in...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：1997-12-01 00:00:00
abstract：BACKGROUND:HDV infection is a cause of severe liver disease. Diagnosis and monitoring of HDV RNA are important to patient management. Since 2012, a WHO standard for HDV RNA quantification has been available; however, the impact of RNA extraction methods on HDV viral load quantification has never been evaluated. METHOD...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3281
更新日期：2019-01-01 00:00:00
abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2004-12-01 00:00:00
abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Zika virus, a previously neglected mosquito-borne virus, is prompting worldwide concern because of its connection with congenital defects, Guillain-Barré syndrome, meningoencephalitis and myelitis in infected individuals. However, no specific antiviral therapy is available at present. In this study, we inves...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3180
更新日期：2017-01-01 00:00:00
abstract：:Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Virological success (VS) and immunological reconstitution (IR) of antiretroviral-naive HIV-1-infected patients with pre-therapy viral load (VL) >500,000 copies/ml was assessed after 12 months of treatment according to initial drug-class regimens. METHODS:An observational multicentre retrospective study was ...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP3197
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Antibodies to liver-kidney microsome type 1 (anti-LKM-1), which are a marker of autoimmune hepatitis, are found in a minority of patients with chronic hepatitis C virus (HCV) infection. Whether interferon/ribavirin therapy is safe and effective in these patients is unclear. AIM:To describe the prevalence, c...
journal_title：Antiviral therapy
pub_type： 临床试验,杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment. METHODS:A total of 243 patients from Cameroon receiving d4T or zidovudine (AZT) in combination with lamivudine and efavirenz or nevirapine for >6 months were clinically assesse...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP1664
更新日期：2010-01-01 00:00:00
abstract：:HBV is a hepatotropic and non-cytopathic virus that causes more than one million deaths annually from liver cirrhosis and hepatocellular carcinoma. As the virus itself is non-cytopathic, it is widely accepted that both viral control and liver pathology are mediated by the host immune system. Until recently, the focus ...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP1620
更新日期：2010-01-01 00:00:00
abstract：BACKGROUND:Scavenger receptor class B type-1 (SR-B1) is one of the many receptors used by HCV to infect hepatocytes. It is used by the virus not only to directly infect cells but also to facilitate cell-to-cell transmission of the virus. Agents such as anti-human SR-B1 (anti-hSR-B1) antibodies represent potential thera...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2570
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:The increased risk for cardiovascular disease (CVD) in HIV is well established. Despite high prevalence of viral hepatitis coinfection with HIV, there are few studies on the risk of CVD amongst antiretroviral therapy (ART)-treated coinfected patients. METHODS:Ontario HIV Treatment Network Cohort Study parti...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2724
更新日期：2014-01-01 00:00:00
abstract：BACKGROUND:Ribavirin augments sustained virological response when administered with pegylated interferon for the treatment of chronic HCV infection. The impact of ribavirin plasma concentration on outcome in individuals receiving interferon-free regimens has not been evaluated. METHODS:Stored plasma samples were retri...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：10.3851/IMP2984
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:Single-drug class regimens with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are generally not recommended as initial therapy because they are inferior compared with therapy with two NRTIs plus efavirenz. However, triple-NRTI combinations can be useful in specific circumstances such as in t...
journal_title：Antiviral therapy
pub_type： 杂志文章,meta分析,评审
doi：10.3851/IMP2726
更新日期：2014-01-01 00:00:00
abstract：BACKGROUND:Hepatitis C virus genotype 1B responds poorly to treatment with interferon, in contrast to the more interferon-sensitive genotypes 2 and 3. Studies on combination therapy regimens with PEG-interferon and ribavirin report sustained response rates that generally do not exceed 50%, in contrast to sustained resp...
journal_title：Antiviral therapy
pub_type： 杂志文章,meta分析
doi：
更新日期：2004-04-01 00:00:00
abstract：BACKGROUND:Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients. OBJECTIVES:To identify prognostic factors of acute liver enzyme abnormalities in HIV-HBV-coinfected patients with a focus on the putative role of antiretroviral drugs. DESIGN:Da...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：
更新日期：2007-01-01 00:00:00
abstract：BACKGROUND:Damage to mitochondria (mt) is a major side effect of highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI). Such damage is associated with the onset of lipodystrophy in HAART-treated HIV+ patients. To further investigate mt changes during this syndrom...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2005-01-01 00:00:00
abstract：BACKGROUND:HIV type-1 (HIV-1) has been shown to be frequently transmitted by acutely infected patients. We investigated the relationship between the dynamics of HIV-1 transmission within recently infected patients, the HIV-1 variability and the transmission of antiretroviral drug resistance. METHODS:We included patien...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Lamivudine (3TC) therapy can cause the emergence of M1841/V. Previous studies suggest a higher fidelity of the mutant reverse transcriptase and lower replication capacity of the mutant virus. No data exist from clinical comparative studies evaluating the benefit of M1841/V in patients receiving combination a...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...
journal_title：Antiviral therapy
pub_type： 杂志文章,多中心研究
doi：10.3851/IMP2972
更新日期：2016-01-01 00:00:00
abstract：BACKGROUND:Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for HIV-1 infected, antiretroviral treatment-naive adults based on data from two Phase III trials. In the screening population, the prevalence of 49 NNRTI resistance-associated mutations (RAMs) and the impact of allowed...
journal_title：Antiviral therapy
pub_type： 杂志文章,随机对照试验
doi：10.3851/IMP2358
更新日期：2013-01-01 00:00:00
abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...
journal_title：Antiviral therapy
pub_type： 杂志文章,评审
doi：10.3851/IMP1982
更新日期：2011-01-01 00:00:00
abstract：:Solid organ transplantation in HIV-infected individuals requires concomitant use of immunosuppressants and antiretrovirals that may cause significant drug interactions. Here we report on a peculiar pharmacokinetic interaction between tacrolimus and protease inhibitors (PIs) which occurred in four HIV-infected liver tr...
journal_title：Antiviral therapy
pub_type： 杂志文章
doi：
更新日期：2008-01-01 00:00:00
